Vesicular monoamine transport inhibitors: Novel action at calcium channels to prevent catecholamine secretion

Hypertension

Volumn 28, Issue 3, 1996, Pages 414-420

  Mahata, Manjula ^b   Mahata, Sushil K ^b   Parmer, Robert J ^b   O'Connor, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NONE

Author keywords

calcium antagonists; calcium channels; catecholamines; dihydropyridines; PC12 cells; reserpine; tetrabenazine

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; NICOTINE; NICOTINIC AGENT; NIFEDIPINE; NITRENDIPINE; NORADRENALIN; RESERPINE; TETRABENAZINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CATECHOLAMINE RELEASE; CATTLE; CELL MEMBRANE DEPOLARIZATION; CHROMAFFIN CELL; CONTROLLED STUDY; DRUG MECHANISM; HYPERTENSION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SYMPATHETIC NERVE CELL;

EID: 0029839705     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.414     Document Type: Article

References (37)

1. Vakil RJ. Clinical trial of rauwolfia serpentina in essential hypertension. Br Heart J. 1949;11:350-355.
2. Mason DT, Braunwald E. Effects of guanethidine, reserpine, and methyldopa on reflex venous and arterial constriction in man. J Clin Invest. 1964;43:1449-1463.
3. Ganett RL, Canver O Jr, Douglas BH. Effects of reserpine on blood pressure and vascular electrolytes in hypertension. Eur J Pharmacol. 1967;2:236-238.
4. Smith WM, Thurm RH, Brown LA. Comparative evaluation of Rauwolfia whole root and reserpine. Arch Int Pharmacodyn Ther. 1969; 151:76-85.
5. Fries ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents. JAMA. 1958;166:137-140.
6. Fries ED. Reserpine in hypertension: present status. Am Fam Physician. 1975;11:120-122.
7. Dollery CT. Pharmacological basis for combination therapy of hypertension. Annu Rev Pharmacol Toxicol. 1977;17:311-323.
8. Kirshner N, Rorie M, Kamin DL. Inhibition of dopamine uptake in vitro by reserpine administered in vivo. J Pharmacol Exp Ther. 1963;141:285-289.
9. Slotkin TA, Edwards K. Effects of reserpine on the content and properties of rat adrenal medullary storage vesicles. Biochem Pharmacol. 1973;22:549-560.
10. Kanner BI, Fishkes H, Maron R, Sharon B, Schuldiner S. Reserpine as a competitive and reversible inhibitor of the catecholamine transporter of bovine chromaffin granules. FEBS Lett. 1979;100:175-180.
11. Carmichael SW, Weber A, Winkler H. Uptake of nucleotides and catecholamines by chromaffin granules from pig and horse adrenal medulla. J Neurochem. 1980;35:270-272.
12. Takiyyuddin MA, Brown MR, Dinh TQ, Cervenka JH, Braun SD, Parmer RJ, Kennedy B, O'Connor DT. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol. 1994;14:187-200.
13. Kirshner N. Uptake of catecholamines by a particulate fraction of the bovine adrenal medulla. J Biol Chem. 1962;237:2311-2317.
14. Henry J-P, Gasnier B, Roisin M-P, Isambert M-F, Scherman D. Molecular pharmacology of the monoamine transporter of the chromaffin granule membrane. Ann N Y Acad Sci. 1987;493:194-206.
15. Van Breenan CV, Lukeman S, Cauvin C. A theoretic consideration on the use of calcium antagonists in the treatment of hypertension. Am J Med. 1984;77:26-30.
16. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980;46:1047-1058.
17. Braunwald E. Mechanism of action of calcium channel blocking agent. N Engl J Med. 1982;307:1618-1627.
18. Massie BM, Hirsch AT, Inouye IK, Tubau JF. Calcium channel blockers as antihypertensive agents. Am J Med. 1984;77:135-142.
19. Frishman WH, Charlap S, Ocken S, Spivack C. Calcium channel blockers and systemic hypertension. J Clin Hypertens. 1985;2:107-122.
20. Terland O, Gronberg M, Flatmark T. The effect of calcium channel blockers on the H(+)-ATPase and bioenergetics of catecholamine storage vesicles. Eur J Pharmacol. 1991;207:37-41.
21. Greene LA, Tischler AS. Establishment of a noradrenergic clonal cell line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976;73:2424-2428.
22. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Barbosa JA, O'Connor DT. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation. 1990;81:185-195.
23. Farmer RJ, Xi X-P, Wu HJ, Helman LJ, Petz LN. Secretory protein traffic: chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest. 1993;92:1042-1054.
24. 2+ influx mechanism. J Biol Chem. 1987;262: 16963-16968.
25. 3H]-nitrendipine. Mol Pharmacol. 1984;25:235-241.
26. Wagner J, Snowman A, Biswas A, Olivera S, Snyder SH. Omega-conotoxin GVIA binding to a high-affinity receptor in the brain: characterization, calcium sensitivity and solubilization. J Neurosci. 1988; 8:3354-3359.
27. Holz RW, Bittner MA, Senter RA. Regulated exocytotic fusion I: chromaffin cells and PC12 cells. Methods Enzymol. 1992;219:165-178.
28. Cheek TR, Barry VA. Stimulus-secretion coupling in excitable cells: a central role for calcium. J Exp Biol. 1993;184:183-196.
29. Firestone JA, Browning MD. Calcium signaling in bovine adrenal chromaffin cells: additive effects of histamine and nicotine. Synapse. 1994;17:268-274.
30. Satoh T, Moriyama T, Kuriki H, Karaki H. Calcium channel blocker-like action of reserpine in smooth muscle. Jpn J Pharmacol. 1992; 60:291-293.
31. Zeitune MG, Bazerque PM. Reserpine non-selectively inhibits rat uterus contraction in vitro. Gen Pharmacol. 1991;22:419-427.
32. Scriabine A. Reserpine. In: Scriabine A, ed. Pharmacology of Anti-hypertensive Drugs. New York, NY: Raven Press Publishers; 1980: 119-125.
33. Stitzel RE. The biological fate of reserpine. Pharmacol Rev. 1977; 28:180-205.
34. Triggle DJ. Biochemical and pharmacologic differences among calcium channel antagonists: clinical implications. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus Inc; 1992:1-27.
35. Catterall WA. Structure and function of voltage-sensitive ion channels. Science. 1988;242:50-61.
36. Morris AD, Meredith PA, Reid JL. Pharmacokinetics of calcium antagonists: implications for therapy. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus Inc; 1992:49-67.
37. Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension. 1995; 26:143-149.